• NICE rejects rare eye disease drug pharmatimes
    March 21, 2018
    Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
PharmaSources Customer Service